SUMMARY
From 1982 to 1995, programmed ventricular stimulation (PVS) was a major technique of screening patients at risk for ventricular tachycardia (VT) and VT-related sudden death (1-3) . During this time PVS was not considered advantageous for risk stratification in coronary heart disease since implantable cardioverter defibrillators (ICD): a number of landmark trials have shown a benefit of prophylactic ICD implantation in patients with only low left ventricular ejection fraction (LVEF) (4,5) . Now, the guidelines recommend the systematic implantation of ICD in patients with history of myocardial infarction (MI) (more than 6 weeks) and LVEF lower than 30% (6). However, proarrhythmic effect of ICD and other complications were reported (7-9) . More, inducible VT remains an important and independent factor of cardiac mortality (10) .
Yet, often PVS is still used after the implantation of ICD mainly for VT ablation. PVS remains a reliable method of screening the risk of sudden death in ischemic heart disease with LVEF more than 30%.
1) What are we awaiting from PVS?
PVS is used to induce a monomorphic VT indicating the possible presence of a reentrant circuit and a risk of VT.
There are two indications of PVS:
-The main benefit is the diagnosis and the evaluation of the mechanism of a wide QRS tachycardia or the diagnosis of symptoms of tachycardia. The method remains always essential (11).
-The second benefit which is actually debated is the risk stratification of patients with MI: the method is useful to predict a risk of VT (1-3) , but is not considered to be beneficial to predict a risk of sudden death; sudden death has multiple origins as VT degenerating into ventricular fibrillation (VF) (20 to 30%), asystole associated or not to a complete atrioventricular block (25%) or primary VF. 2) The protocol is well-codified:
CORRESPONDENCE
Complete electrophysiological study is recommended, including a right atrial pacing. Then stimulation of right ventricle with 1 and 2 extrastimulus is performed at two cycles in right ventricular apex and then in the infundibulum. If VT is not induced a third extrastimulus is added in both sites. The increasing number of extrastimuli increases the sensitivity, but decreases the specificity with a risk of induction of a nonspecific arrhythmia as VF.
A short coupling lower than 200 ms is also associated with a risk of VF induction.
PVS should be repeated after isoproterenol infusion in the case of stress of exercise-related syncope or tachycardia.
3) The results are well-known after MI:
The sensitivity of PVS in patients with spontaneous VT is excellent (90%) (11) .
In asymptomatic patients, the induction of a monomorphic sustained VT is always pathological and associated with a risk of VT-related sudden death and spontaneous VT (1-3) ; only ICD implantation decreases the risk of sudden death in these patients (4) . The interest of the method was debated after the Multicenter Automatic Defibrillator Implantation Trial II (MADIT) (8) , where low LVEF, less than 30 % was only used for the indication of ICD with a significant decrease of sudden deaths.
The induction of a ventricular flutter (monomorphic VT with a rate higher than 270 bpm) occurring in 10 % of asymptomatic patients with MI is more controversial and is considered as pathological only in MADIT I study (4) .
The induction of a polymorphic VT (VF) is without significance except after resuscitated sudden death (1-3) .
Several studies have reported the good prognosis of patients with negative PVS (1-3, 10) except in a sub study of MADIT II study: patients with negative study had more VF than those with inducible VF (12).
4) Actual and future indications of PVS after MI:
The assessment of cardiac syncope occurring in a patient with LVEF higher than 30/35% is a class IB recommendation (13) even when a possible aetiology is suspected: this cause may hide another. Complete electrophysiological study might be indicated in patient with MI, syncope and LVEF lower than 30% when ICD implantation can be discussed in the case of advanced age or poor general condition to find another cause of syncope as supraventricular tachycardia or conduction disorder.
PVS is used for the risk stratification after MI in the case of LVEF between 40% and 30/35 % when nonsustained VT is noted at Holter monitoring (MADIT I) (IB recommendation) (6) .
We have to remember the limits of the prognostic value of LVEF (14, 15) with a higher risk of sudden death in patients with LVEF higher than 30% and another risk factor than in patients with only a LVEF lower than 30 % and no other risk factor.
The sub analysis of the Multicenter Unsustained Tachycardia Trial (MUSTT) (10) and MADIT 2 studies (12) reports more VT in patients with inducible VT. The prognosis is worse in patients studied in the first 6 months and inducible VT in MUSTT study (16) .
Furthermore, PVS performed soon after MI (day 9) identify individuals at risk or not (17, 18) . The same group reported recently the role of PVS to identify the high-risk patients for ICD implantation, where PVS was used post-MI. The patient group had a LVEF less than 40% early post MI and underwent primary percutaneous coronary intervention for ST elevation MI. The prospective study of early ICD implantation 6 to 40 days post-MI (Defibrillator in Acute Myocardial Infarction Trial, DINAMIT) (19) and a retrospective analysis of data from the MADIT II trial (12) failed to show a survival benefit for patients with ICD implantation in the early post-MI period. The recent studies suggest that patients may benefit from an ICD if they have an inducible ventricular tachyarrhythmia in the early post MI period. A large majority (two thirds) of patients with a negative PVS were at significantly lower risk of arrhythmic events without a defibrillator in the long term.
At least PVS is indicated before VT ablation and the latter indication is now raising either in patients with spontaneous VT and LVEF more than 35/40 % or in patients with VT and before ICD implantation (VTACH) to reduce the recurrences (20) . PVS is combined with imaging methods.
In conclusion, although PVS is now less frequently indicated after MI than 10 years ago, it is still recommended (IB) in patients with syncope and LVEF more than 30-35% or in asymptomatic patients with a LVEF between 30-40% and with non sustained VT at Holter monitoring. Combined with imaging methods, PVS could be widely used again during VT ablation. Patients could benefit from PVS to better risk-identify patients who may be at high risk of VT or arrhythmic events in the early post-MI period. 
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